drugset
drugset / Trial / NCT05846659

Study of PULSAR-ICI +/- IMSA101 in Patients With Oligoprogressive Solid Tumor Malignancies

NCT05846659 ↗

Phase 2 Terminated 16 enrolled ImmuneSensor Therapeutics Inc.
RandomizedParallel-groupOpen-labelTreatment

Summary

Phase 2, open-label, multicenter, randomized study comparing the safety and efficacy of personalized ultra-fractionated stereotactic adaptive radiotherapy (PULSAR) combined with immune checkpoint inhibitor (ICI) immunotherapy (PULSAR-ICI) + IMSA101 and PULSAR-ICI alone in patients with oligoprogressive solid tumor malignancies after prior anti-cancer therapy.

Timeline

Start
2023-07-07
Primary completion
2024-11-20
Completion
2024-11-20

Drugs

EvaluationDrugModalityDoseRoute
Subject IMSA101 Small molecule — Other
Background Nivolumab Monoclonal antibody — —
Background Pembrolizumab Monoclonal antibody — —

Indications

No indication recorded.